Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
2022-004165-20Phase 3Active
- Sponsor
- CHU de Poitiers
- Start
- Jan 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib, nilotinib, dasatinib and bosutinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by CHU de Poitiers. Primary endpoint: Treatment-free remission at 24 months. Started Jan 2023; status: active.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2022-004165-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004165-20.